Literature DB >> 17371864

The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor.

Shee Eun Lee1, Soo Young Kim, Choon Mee Kim, Mi-Kwang Kim, Young Ran Kim, Kwangjoon Jeong, Hwa-Ja Ryu, Youn Suhk Lee, Sun Sik Chung, Hyon E Choy, Joon Haeng Rhee.   

Abstract

We have suggested an important role of the pyrH gene during the infectious process of Vibrio vulnificus. Previously, we have identified 12 genes expressed preferentially during human infections by using in vivo-induced antigen technology. Among the in vivo-expressed genes, pyrH encodes UMP kinase catalyzing UMP phosphorylation. Introduction of a deletion mutation to the pyrH gene was lethal to V. vulnificus, and an insertional mutant showed a high frequency of curing. We constructed a site-directed mutant strain (R62H/D77N) on Arg-62 and Asp-77, both predicted to be involved in UMP binding, and characterized the R62H/D77N strain compared with the previously reported insertional mutant. We further investigated the essential role of the pyrH gene in the establishment of infection using the R62H/D77N strain. Cytotoxicity was decreased in the R62H/D77N strain, and the defect was restored by an in trans complementation. The intraperitoneal 50% lethal dose of the R62H/D77N strain increased by 26- and 238,000-fold in normal and iron-overloaded mice, respectively. The growth of the R62H/D77N strain in 50% HeLa cell lysate, 100% human ascitic fluid, and 50% human serum was significantly retarded compared to that of the isogenic wild-type strain. The R62H/D77N mutant also had a critical defect in the ability to survive and replicate even in iron-overloaded mice. These results demonstrate that pyrH is essential for the in vivo survival and growth of V. vulnificus and should be an attractive new target for the development of antibacterial drugs and replication-controllable live attenuated vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371864      PMCID: PMC1932866          DOI: 10.1128/IAI.01499-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

Review 1.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Structure-function relationships of UMP kinases from pyrH mutants of Gram-negative bacteria.

Authors:  Hiroshi Sakamoto; Stéphanie Landais; Cécile Evrin; Christine Laurent-Winter; Octavian Bârzu; Rod A Kelln
Journal:  Microbiology (Reading)       Date:  2004-07       Impact factor: 2.777

Review 3.  Epidemiology and pathogenesis of Vibrio vulnificus.

Authors:  M S Strom; R N Paranjpye
Journal:  Microbes Infect       Date:  2000-02       Impact factor: 2.700

4.  Control of capsular polysaccharide chain length by UDP-sugar substrate concentrations in Streptococcus pneumoniae.

Authors:  Christy L Ventura; Robert T Cartee; W Thomas Forsee; Janet Yother
Journal:  Mol Microbiol       Date:  2006-06-15       Impact factor: 3.501

5.  Regulation of Vibrio vulnificus virulence by the LuxS quorum-sensing system.

Authors:  Soo Young Kim; Shee Eun Lee; Young Ran Kim; Choon Mee Kim; Phil Youl Ryu; Hyon E Choy; Sun Sik Chung; Joon Haeng Rhee
Journal:  Mol Microbiol       Date:  2003-06       Impact factor: 3.501

6.  Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine.

Authors:  Ho Young Kang; Jay Srinivasan; Roy Curtiss
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  UMP kinase from the Gram-positive bacterium Bacillus subtilis is strongly dependent on GTP for optimal activity.

Authors:  Cristina Gagyi; Nadia Bucurenci; Ovidiu Sîrbu; Gilles Labesse; Mihaela Ionescu; Augustin Ofiteru; Liliane Assairi; Stéphanie Landais; Antoine Danchin; Octavian Bârzu; Anne-Marie Gilles
Journal:  Eur J Biochem       Date:  2003-08

8.  Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients.

Authors:  Young Ran Kim; Shee Eun Lee; Choon Mee Kim; Soo Young Kim; Eun Kyoung Shin; Dong Hyeon Shin; Sun Sik Chung; Hyon E Choy; Ann Progulske-Fox; Jeffrey D Hillman; Martin Handfield; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Comparative modelling and immunochemical reactivity of Escherichia coli UMP kinase.

Authors:  Gilles Labesse; Nadia Bucurenci; Dominique Douguet; Hiroshi Sakamoto; Stéphanie Landais; Cristina Gagyi; Anne-Marie Gilles; Octavian Bârzu
Journal:  Biochem Biophys Res Commun       Date:  2002-05-31       Impact factor: 3.575

10.  Broad host range DNA cloning system for gram-negative bacteria: construction of a gene bank of Rhizobium meliloti.

Authors:  G Ditta; S Stanfield; D Corbin; D R Helinski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  17 in total

1.  Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms.

Authors:  Tae Hee Lee; Sun-Shin Cha; Chang-Seop Lee; Joon Haeng Rhee; Kyung Min Chung
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  PUMPKIN, the Sole Plastid UMP Kinase, Associates with Group II Introns and Alters Their Metabolism.

Authors:  Lisa-Marie Schmid; Lisa Ohler; Torsten Möhlmann; Andreas Brachmann; Jose M Muiño; Dario Leister; Jörg Meurer; Nikolay Manavski
Journal:  Plant Physiol       Date:  2018-11-08       Impact factor: 8.340

3.  Temperature Change Induces the Expression of vuuA Encoding Vulnibactin Receptor and crp Encoding Cyclic AMP Receptor Protein in Vibrio vulnificus.

Authors:  Choon-Mee Kim; Young-Joon Ahn; Seong-Jung Kim; Dae-Heung Yoon; Sung-Heui Shin
Journal:  Curr Microbiol       Date:  2016-03-25       Impact factor: 2.188

4.  In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

Authors:  Seong Eun Kim; Hee Kyung Kim; Su-Mi Choi; Yohan Yu; Uh Jin Kim; Kalifa Sanneh Darboe; Seung-Ji Kang; Kyung-Hwa Park; Gaeun Kang; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hee-Chang Jang
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

5.  Identification of Burkholderia cenocepacia strain H111 virulence factors using nonmammalian infection hosts.

Authors:  Stephan Schwager; Kirsty Agnoli; Manuela Köthe; Friederike Feldmann; Michael Givskov; Aurelien Carlier; Leo Eberl
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

6.  Global gene expression as a function of the iron status of the bacterial cell: influence of differentially expressed genes in the virulence of the human pathogen Vibrio vulnificus.

Authors:  Alejandro F Alice; Hiroaki Naka; Jorge H Crosa
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

7.  Effects of temperature, growth phase and luxO-disruption on regulation systems of toxin production in Vibrio vulnificus strain L-180, a human clinical isolate.

Authors:  Abdelaziz Elgaml; Kazutaka Higaki; Shin-ichi Miyoshi
Journal:  World J Microbiol Biotechnol       Date:  2013-09-26       Impact factor: 3.312

8.  All Three TonB Systems Are Required for Vibrio vulnificus CMCP6 Tissue Invasiveness by Controlling Flagellum Expression.

Authors:  Tra-My Duong-Nu; Kwangjoon Jeong; Seol Hee Hong; Hong-Vu Nguyen; Van-Hoan Ngo; Jung-Joon Min; Shee Eun Lee; Joon Haeng Rhee
Journal:  Infect Immun       Date:  2015-11-02       Impact factor: 3.441

9.  Identification of drug target candidates of the swine pathogen Actinobacillus pleuropneumoniae by construction of protein-protein interaction network.

Authors:  Siqi Li; Zhipeng Su; Chengjun Zhang; Zhuofei Xu; Xiaoping Chang; Jiawen Zhu; Ran Xiao; Lu Li; Rui Zhou
Journal:  Genes Genomics       Date:  2018-05-03       Impact factor: 1.839

10.  Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery.

Authors:  Hyun Uk Kim; Soo Young Kim; Haeyoung Jeong; Tae Yong Kim; Jae Jong Kim; Hyon E Choy; Kyu Yang Yi; Joon Haeng Rhee; Sang Yup Lee
Journal:  Mol Syst Biol       Date:  2011-01-18       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.